1. Home
  2. RIGL vs PLL Comparison

RIGL vs PLL Comparison

Compare RIGL & PLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • PLL
  • Stock Information
  • Founded
  • RIGL 1996
  • PLL 2016
  • Country
  • RIGL United States
  • PLL United States
  • Employees
  • RIGL N/A
  • PLL N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • PLL Other Metals and Minerals
  • Sector
  • RIGL Health Care
  • PLL Basic Materials
  • Exchange
  • RIGL Nasdaq
  • PLL Nasdaq
  • Market Cap
  • RIGL 247.1M
  • PLL 238.0M
  • IPO Year
  • RIGL 2000
  • PLL 2017
  • Fundamental
  • Price
  • RIGL $22.07
  • PLL $11.46
  • Analyst Decision
  • RIGL Buy
  • PLL Buy
  • Analyst Count
  • RIGL 4
  • PLL 8
  • Target Price
  • RIGL $31.13
  • PLL $22.63
  • AVG Volume (30 Days)
  • RIGL 151.9K
  • PLL 963.8K
  • Earning Date
  • RIGL 11-07-2024
  • PLL 11-12-2024
  • Dividend Yield
  • RIGL N/A
  • PLL N/A
  • EPS Growth
  • RIGL N/A
  • PLL N/A
  • EPS
  • RIGL 0.22
  • PLL N/A
  • Revenue
  • RIGL $156,374,000.00
  • PLL $66,444,999.00
  • Revenue This Year
  • RIGL $38.26
  • PLL $155.85
  • Revenue Next Year
  • RIGL $24.21
  • PLL $13.29
  • P/E Ratio
  • RIGL $99.67
  • PLL N/A
  • Revenue Growth
  • RIGL 19.95
  • PLL N/A
  • 52 Week Low
  • RIGL $7.48
  • PLL $6.57
  • 52 Week High
  • RIGL $22.85
  • PLL $31.82
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 83.76
  • PLL 46.51
  • Support Level
  • RIGL $13.91
  • PLL $12.82
  • Resistance Level
  • RIGL $14.70
  • PLL $14.16
  • Average True Range (ATR)
  • RIGL 1.04
  • PLL 1.15
  • MACD
  • RIGL 0.50
  • PLL -0.25
  • Stochastic Oscillator
  • RIGL 91.59
  • PLL 29.72

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About PLL Piedmont Lithium Inc.

Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.

Share on Social Networks: